Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 6/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125619 | 0.91 | ALDH1A1 (0.35) | NAMPT | |
| SCHEMBL4125903 | 0.85 | NAMPT (0.38) | HTTATMNAMPTCYP2C9TDP1 | |
| SCHEMBL4138207 | 0.85 | NAMPT (0.38) | HTTATMNAMPTCYP2C9TDP1 | |
| SCHEMBL4130696 | 0.82 | SLC22A12 (0.36) | NAMPTCYP2C9TDP1 | |
| Hydrochloric Acid SCHEMBL4131263 | 0.82 | CYP2A6 (0.39) | NAMPTCYP2C9ABCB1ABCC1 | |
| SCHEMBL4120230 | 0.82 | NAMPT (0.38) | NAMPT | |
| SCHEMBL3652836 | 0.81 | AGTR2 (0.34) | NAMPTCYP2C9GRM4 | |
| SCHEMBL4127140 | 0.81 | NAMPT (0.33) | NAMPTABCB1ABCC1 | |
| SCHEMBL4117665 | 0.80 | LIPG (0.34) | NAMPT | |
| SCHEMBL4125700 | 0.78 | ALDH1A1 (0.38) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | HTT 3967/4885ATM 4850/4885NAMPT 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.